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Patient outcomes and thoracic aortic volume and
morphologic changes following thoracic
endovascular aortic repair in patients with
complicated chronic type B aortic dissection
Iden David Andacheh, MD, Carlos Donayre, MD, Fiezel Othman, MD, Irwin Walot, MD,
George Kopchok, BS, and Rodney White, MD, Torrance, Calif
Objective: True and false lumen changes and patient outcomes following thoracic endovascular aortic repair (TEVAR) for patients
with stable type B dissection have been described by the The Investigation of Stent Grafts in Aortic Dissection (INSTEAD) trial.
However, these changes have not been described in TEVAR patients treated for complications of chronic dissection.
Methods: A single-institution study was conducted of 73 prospectively evaluated patients treated for complications of
chronic type B dissection from 2002 to 2010. Spiral computed tomography reconstructions using M2S (Medical Media
Systems, West Lebanon, NH) were analyzed for sequential changes in aortic volume and diameter during patient
follow-up. Changes in aortic volume and diameter were tabulated as a percent change from preoperative values. Patient
outcomes were determined by sequential evaluations postprocedure.
Results:TEVARwas successfullyperformed in72outof the73patients (99%). Indications for interventionwereaortic enlargement
(n62), failure ofmedicalmanagement (n7), andperforation (n4). The 30-day all-causemortality ratewas 14%; eventswere
due to retrograde dissection (n 4), cardiac-related (n 4), and rupture (n 2). Eleven out of the 72 patients (15%) required a
secondary procedure for endoleak (n 7) and persistent distal perfusion of the false lumen (n 4).Mean percentage expansion of
the thoracic true lumen was noted during the follow-up period: 38%, 46%, 71%, and 114% at 1-, 3-, 6-, and 12-month follow-up,
respectively. Concomitant regression of the thoracic false lumen of 65%, 68%, 84%, and 84% was observed at the same
intervals, respectively. Patients with an initial extension of the thoracic dissection into the infrarenal aorta (n 46) had an increase
in mean percentage change of aortic diameter and volume to 21% and 17% at 1 year, respectively. By contrast, in the patient group
without infrarenal dissection (n 14), the infrarenal aortic diameter and volume remained relatively unchanged at 3% and0.9%,
respectively, at 1-year postintervention.
Conclusions: TEVAR is a potential treatment option for patients experiencing complications of chronic type B dissection. During
follow-up, there is a predictable expansion of the thoracic true lumen and regression of the thoracic false lumen. These findings
correlate with those of the INSTEAD trial, which demonstrated false lumen regression and true lumen expansion in a cohort of
patients with stable type B dissection. However, many patients with extension of thoracic dissection into the infrarenal aorta
demonstrate continued aortic dilation and, on occasion, the need for secondary intervention for persistent distal perfusion. Further
analysis is needed in this subgroup of patients so as to better determine potential predictors and the clinical significance of
post-TEVAR infrarenal expansion.Moreover, further investigationsmay support a role for secondary endovascular intervention in
remedying persistent infrarenal aortic expansion after TEVAR for chronic dissection. (J Vasc Surg 2012;56:644-50.)
i
d
a
p
d
g
T
a
t
t
e
w
s
t
D
s
fThoracic endovascular aortic repair (TEVAR) has
emerged as a treatment option in the management of aortic
dissection.1 TEVAR is being considered as the front-line
therapy for patients with acute descending thoracic dissec-
tion with malperfusion, provided that timely endovascular
intervention is available. Recent series suggest that TEVAR
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644s a promising treatment in the setting of acute type B
issection withmalperfusion, rupture, chest pain, and acute
ortic enlargement.2,3 In this group of patients, there ap-
ears to be favorable and predictable aortic remodeling
uring follow-up after intervention.2 Outcome studies sug-
est that mortality rates at 30 days and 1 year following
EVAR for acute complicated type B dissection are accept-
ble, compared with surgical and medical treatment op-
ions.3
In the setting of chronic type B dissection, defined by
he presence of aortic dissection for greater than 2 weeks,
ndovascular stenting has been debated.4 Of those patients
ith uncomplicated chronic type B dissection, series have
hown that medical management is equal, if not superior,
o TEVAR. The Investigation of Stent Grafts in Aortic
issection (INSTEAD) trial suggests that endovascular
tenting results in a predictable diametric regression of the
alse lumen and expansion of true lumen in patients with
ncomplicated type B dissection. Despite these changes,
w
d
G
R
p
T
e
y
t
p
r
r
r
a
f
r
f
d
w
t
v
b
c
r
p
r
a
T
A
N
N
A
A
I
I
I
A
T
P
3
1
S
P
R
JOURNAL OF VASCULAR SURGERY
Volume 56, Number 3 Andacheh et al 645the 2-year data from the INSTEAD trial concluded that
TEVAR in the setting of stable chronic dissection does not
improve survival nor adverse events, in comparison to med-
ical therapy.5 However, recently presented, yet unpub-
lished 5-year data from the INSTEAD trial show significant
crossover of the medically treated patients to the interven-
tion group.6 The role of TEVAR in patients with compli-
cated chronic aortic dissection, as defined by aortic enlarge-
ment, persistence of symptoms despite medical therapy,
and perforation, is largely unknown.
The purpose of our study is to analyze a cohort of
patients who underwent TEVAR for complications of
chronic type B dissection in a Food and Drug Administra-
tion (FDA)-approved, single-center study. Our analysis
includes patient outcomes, reintervention rates, and aortic
remodeling with follow-up.
METHODS
A total of 73 patients with complicated chronic aortic
dissection were treated as part of an FDA-approved single-
center investigational device exemption (IDE) from 2002
to 2010 at Harbor-UCLA Medical Center in Torrance,
California. Indications for intervention included aneurys-
mal enlargement (n  62), failure of medical management
(n 7), and perforation (n 4). Aneurysmal enlargement
was defined as (1) thoracic aneurysm size of 6 cm or greater
or (2) increase in maximal thoracic aortic diameter of0.5
cm per year on surveillance imaging. Patients categorized as
failing medical management were those who had intracta-
ble chest pain, deteriorating renal function, or refractory
hypertension despite adequate control of blood pressure.
Patients fell into the perforation group if they had a known
type B dissection and evidence of aortic perforation on
computed tomography (CT) imaging.
Endovascular devices used at the time of procedure
were endografts manufactured by Medtronic, Inc (Santa
Rosa, Calif) and included Talent from 2002 to 2008 and
Valiant Captivia from 2008 to 2010. Following TEVAR,
patients were prospectively followed at 1, 3, 6, and 12
months, followed by yearly thereafter unless follow-up
findings warranted more frequent observation. Devices
were deployed via an open femoral approach. Both intra-
vascular ultrasound and angiography were used to assist in
device deployment. Spiral CT imaging was conducted at
each interval with aortic diameter, volume and device con-
figuration using M2S (Medical Media Systems, West Leb-
anon, NH). A sequential chart review was conducted to
assess patient characteristics, outcomes, and reintervention
rates.
Measures of aortic remodeling included maximal tho-
racic aortic diameter, thoracic aorta true lumen volume,
thoracic aorta false lumen volume, maximal infrarenal aor-
tic diameter, and infrarenal aorta total volume. In addition,
values for maximal thoracic true lumen diameter and max-
imal thoracic false lumen diameter were analyzed. Values
were tabulated as a percent change from preoperative aortic
diameter and volume measurements. fStatistical analysis was performed via MedCalc soft-
are; a 2 normal distribution was performed on collected
ata and comparison of means was performed via t-test.
raphical analysis was conducted using Microsoft Excel.
ESULTS
TEVAR was successfully performed in 72 out of the 73
atients (99%) with complicated chronic type B dissection.
he procedure was aborted in one patient as a result of
xcessively tortuous anatomy. Average patient age was 58
ears and average preoperative patient American Associa-
ion of Anesthetists (ASA) score was 3.2. At 30 days, the
rocedure-related mortality rate was 14%. Causes included
etrograde dissection (n  4), cardiac-related (n  4), and
upture (n  2). Two patients had significant procedure-
elated morbidity: one patient had a postoperative stroke and
nother patient had paraplegia following TEVAR (Table I).
Mean patient follow-up was 18 months. During this
ollow-up period, a total of 11 out of the 72 patients (15%)
equired a secondary intervention. The two determinants
or reintervention were endoleak (n  7) and persistent
istal perfusion (n  4). All seven patients with endoleak
ere treated with a second endoluminal procedure. Two of
he patients with persistent distal perfusion were managed
ia endoluminal stent while the other two required a de-
ranching procedure and abdominal aortic exclusion. All-
ause mortality rate at 1 year was 19%; 1-year procedure-
elated mortality was 14%, unchanged from the 30-day
rocedure-related mortality. There were no procedure-
elated deaths following reintervention (Table II).
Expansion of the true lumen, compared with preoper-
tive measurements, was noted in the follow-up period
able I. Patient information
verage age 58 years
umber of male patients 52 (71%)
umber of female patients 21 (29%)
verage ASA score 3
verage follow-up 18 months
ntervention for aortic enlargement 62 (85%)
ntervention for failure of medical management 9 (12%)
ntervention for aortic rupture 2 (3%)
SA, American Association of Anesthetists.
able II. Patient outcomes
rocedure success 72/73 (99%)
0-day procedure-related mortality 10/73 (14%)
Aortic rupture 2/10 (20%)
Retrograde dissection 4/10 (40%)
Cardiac events 4/10 (40%)
-year all-cause mortality 14/73 (19%)
troke rate 1/72 (1%)
araplegia rate 1/72 (1%)
eintervention rate 11/72 (15%)
Endoleak 7/11
Persistent distal perfusion 4/11ollowing TEVAR. Thoracic true lumen volume expanded
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September 2012646 Andacheh et al38% (relative standard deviation [RSTD]  3.1), 46%
(RSTD  2.1), 71% (RSTD  1.3), and 114% (RSTD 
1.2) at 1-, 3-, 6-, and 12-months postprocedure, respec-
tively (Fig 1). True lumen diameter also increased during
follow-up: 2.5% (RSTD  8.8), 2% (RSTD  14.4), 10%
(RSTD  3.0), and 9.5% (RSTD  1.9), respectively (Fig
2). Concomitant regression of the thoracic false lumen was
observed during patient follow-up; thoracic false lumen
volume regressed65% (RSTD 0.59),68% (RSTD
0.66), 84% (RSTD  0.27), and 84% (RSTD  0.13)
at 1-, 3-, 6-, and 12-month follow-ups. Measures of maxi-
mal thoracic false lumen diameter also showed regression
over the follow-up period: 24% (RSTD  1.3), 16%
(RSTD 2.0),27% (RSTD 1.0), and30% (RSTD
1.0) at these intervals, respectively (Fig 3). Overall maximal
thoracic aortic diameter was observed to regress during the
follow-up period: 5% (RSTD 2.1), 4% (RSTD 2.6), 2%
(RSTD  5.5), and 1% (RSTD  19.6) at 1, 3, 6, and 12
months.
Across all patients, infrarenal maximal true lumen
diameter increased in the postprocedure period. At 1, 3,
6, and 12 months, infrarenal true lumen maximal diam-
Fig 1. Percent change of thoracic true lum
Fig 2. Percent change in thoracic true lumen diameter over
time.eter expanded by 9%, 2.5%, 8.5%, and 3% from the wreoperative measurements, respectively (Fig 4). Maxi-
al infrarenal false lumen diameter regressed postinter-
ention: 3%, 3%, 4%, and 3% at 1, 3, 6, and 12 months
Fig 5).
Infrarenal volumetric and diameter changes varied be-
ween those patients who had intervention for type B
issection with infrarenal involvement vs those who did
ot. Of 46 patient with infrarenal extension of the type B
issection, 23 (50%) had increasing infrarenal aortic vol-
me following TEVAR. By comparison, four out of the 14
atients (27%) without infrarenal dissection had infrarenal
ortic volume expansion during patient follow-up. In pa-
ients with infrarenal type B dissection, infrarenal maximal
iameter was seen to increase by an average of 4%, 9%, 6%,
nd 17% at 1, 3, 6, and 12 months. Conversely, in patients
ithout infrarenal dissection, the infrarenal maximal diam-
ter was 1%, 2%, 4%, and 1% at these intervals, respec-
ively (Fig 6; Table III).
Volumetric analysis also indicates infrarenal expansion
ollowing TEVAR in patients with type B dissection with
nfrarenal involvement. In this group, total infrarenal vol-
me was noted to increase by 8%, 11%, 18%, and 22% at 1-,
-, 6-, and 12-months postprocedure. By comparison, in
atients without preoperative infrarenal dissection, vol-
mes were 6%, 5%, 1%, and 3% at these follow-ups,
espectively (Fig 7; Table IV).
ISCUSSION
Patient outcomes in our analysis appear to be com-
arable to the current literature. Recent series suggest a
erioperative mortality rate of 5% to 11% in the setting of
EVAR for complicated type B aortic dissection.7 Al-
hough our 30-day procedure-related mortality rate of
4% may appear high in relation to current studies, one
atient death occurred due to aortic rupture following
EVAR in a patient with Marfan’s syndrome. The other
upture patient was a 78-year-old male who had inter-
ention for aortic enlargement. In addition, one patient
ith cause of death categorized as retrograde dissection
nd thoracic false lumen volume over time.as found to have an ascending dissection on autopsy
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Volume 56, Number 3 Andacheh et al 647that originated from the anastomosis of a previous aortic
graft, done as part of a debranching procedure, and thus
not endograft-related. Therefore, three out of the 72
treated patients, or 4%, had a device-related retrograde
dissection postoperatively. This is comparable with the
retrograde dissection rate seen in prior series.8 Of the
remaining three deaths due to retrograde dissection, two
were individuals who had TALENT grafts placed. Only
Fig 3. Percent change in thoracic f
Fig 4. Percent change in infrarenal
Fig 5. Percent change in infrarenalone out of the 39 patients who had Valiant-Captivia cip-capture devices died secondary to retrograde dissec-
ion. These findings may suggest that the newer tip-
apture devices may reduce the risk of retrograde dissec-
ion-related complications.
The average preoperative patient ASA score of 3.2
uggests that our study population had severe underlying
ystemic illness at baseline. The stroke and paraplegia
ate of 1% noted in our study is also comparable to
umen maximal diameter over time.
lumen maximal diameter over time.
lumen maximal diameter over time.urrent literature. It is worth noting that the patient who
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September 2012648 Andacheh et alhad paraplegia was an individual who had prior open
repair of ascending and descending dissection, but had
subsequently developed descending dissection distal to
the previous graft anastamosis.
The observed reintervention rate of 15% is acceptable
and similar to other published data. Other investigations
have reported reintervention rates as high as 22% following
TEVAR for complicated type B aortic dissection.8,9 There
were no procedure-related deaths following reintervention
in the study cohort.
As a referral institution, there were limitations to cer-
tain aspects of patient data. The exact duration of chronic
aortic dissection was known in less than half of all patients.
As a result, we were unable to reliably quantify the average
age of chronic dissection in our patient population. There-
fore, we were unable to perform analysis on duration of
disease and aortic remodeling following TEVAR.
Our analysis suggests that aortic remodeling follow-
ing TEVAR for complicated chronic type B dissection
occurs in a predictable fashion. Diametric and volumetric
true lumen expansion and false lumen regression is ob-
served after intervention in this group of patients. The
INSTEAD trial, which looked at patients with uncom-
plicated type B dissection, had similar findings in their
study cohort. Other series have similarly shown favorable
aortic remodeling following thoracic intervention for
type B dissection.10 While the INSTEAD trial looked at
Fig 6. Percent change in maximal infrarenal diameter: P
patients without preoperative evidence of infrarenal disse
Table III. Comparison of average percent change in
infrarenal aortic diameter
Follow-up
Infrarenal
dissection
group
No
infrarenal
dissection
group P value
1 month 4.25% 0.72% .46
3 months 9.34% 1.64% .43
6 months 5.93% 4.10% .72
12 months 16.61% 0.57% .24
24 months 9.64% 0.64% .18maximal thoracic false and true lumen diameter changes, rheir analysis did not include volumetric changes. More-
ver, INSTEAD and prior studies did not look at changes
n the infrarenal aorta following endoluminal intervention.
hile the thoracic aorta appears to remodel in a predictable
anner following TEVAR, remodeling of the infrarenal aorta
oes not. Our volumetric and diameter measurements sug-
est that postprocedure infrarenal remodeling may be influ-
nced by the extent of type B dissection.
In patients with thoracic dissection extending below
he renal arteries, there is infrarenal aortic expansion
ollowing TEVAR. Both the infrarenal aortic diameter
nd volume increased following intervention in this pa-
ient subgroup. Comparatively, individuals without in-
rarenal dissection involvement had relatively no changes
n infrarenal diameter and volume following thoracic
ndovascular intervention. Proposed mechanisms for
ersistent distal perfusion include (1) distal re-entry
ears, (2) retrograde filling of the false lumen, and (3)
inetic motion of the dissection flap.4 The first of these
echanisms suggests that re-entry tears in the intimal
ap may be present that are not visualized on CT imag-
ng. As a result, these re-entry segments may provide
erfusion of the false lumen. The second mechanism
roposes retrograde perfusion of the false lumen
hrough visceral branch vessels. The role of intimal flap
otion has been analyzed in recent series.11 It is con-
eivable that unimpeded septal motion may prevent stag-
ation of flow in the aortic false lumen, thereby prevent-
ng thrombosis.
The finding of persistent infrarenal aortic expansion
ost-TEVAR is not a new observation. Prior literature
as identified that as many as 50% to 70% of all patients
xperience abdominal aortic expansion following endo-
uminal exclusion for thoracic aortic dissection.12 How-
ver, previous studies did not describe the patient sub-
roup in which this remodeling occurs. Our study
uggests that the infrarenal aortic enlargement occurs to
greater degree in those patients who have preinterven-
ion evidence of type B dissection extending below the
ts with preoperative evidence of infrarenal dissection vs
.atienenal arteries.
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Volume 56, Number 3 Andacheh et al 649A potential remedy for persistent infrarenal aortic
perfusion following TEVAR has been proposed in the
literature. The PETTICOAT technique involves the
placement of bare metal scaffolding stents as an adjunct
to or staged procedure following TEVAR. Nienaber and
colleagues performed this technique in 12 patients pre-
viously treated by TEVAR for complications of chronic
dissection. Each patient had progressive infrarenal aortic
enlargement following thoracic intervention. Following
deployment of the bare metal scaffolding stents, all
patients demonstrated improved infrarenal aortic re-
modeling after 1 year.13
CONCLUSIONS
TEVAR is an appropriate treatment option for individuals
with complications of chronic aortic dissection. However,
infrarenal involvement of type B dissection appears to be a risk
factor for progressive infrarenal aortic enlargement following
thoracic intervention. Further analysis, longer follow-up, and
a larger study cohort are necessary to adequately power statis-
tical analyses. At the minimum, the findings of this analysis
should prompt clinicians to include the abdominal aorta on
follow-up CT imaging following TEVAR. Analysis of current
tip-capture devices should include rates of retrograde dissec-
tion and associated mortality; the newer tip-capture devices
may decrease the risk of this dreaded complication in relation
Fig 7. Percentage change in total infrarenal volume: P
patients without preoperative evidence of infrarenal disse
Table IV. Comparison of average percent change in
infrarenal aortic volume
Follow-up
Infrarenal
dissection
group
No
infrarenal
dissection
group P value
1 month 8.04% 6.30% .06
3 months 10.59% 5.31% .70
6 months 17.34% 0.90% .17
12 months 21.61% 5.02% .20
24 months 17.90% 12.14% .81to older devices. Moreover, continued investigation of newerndovascular devices and the use of large open stents should
e pursued to address the issue of infrarenal aortic expansion
ollowing thoracic intervention.
UTHOR CONTRIBUTIONS
onception and design: IA, CD, IW, GK, RW
nalysis and interpretation: IA, CD, FO, GK, RW
ata collection: IA, FO, GK
riting the article: IA, CD, FO, RW
ritical revision of the article: CD, IW, RW
inal approval of the article: CD, IW, RW
tatistical analysis: IA
btained funding: Not applicable
verall responsibility: IA
EFERENCES
1. Desai ND, Pochettino A, Szeto WY, Moser GW, Moeller PJ, Sodhi N,
et al. Thoracic endovascular aortic repair: evolution of therapy, patterns
of use, and results in a 10-year experience. J Thorac Cardiovasc Surg
2011;142:587-94.
2. Kim KMDonayre CE, Reynolds TS, Kopchok GE,Walot I, et al. Aortic
remodeling, volumetric analysis, and clinical outcomes of endoluminal
exclusion of acute complicated type B thoracic aortic dissections: J Vasc
Surg 2011;54316-24; discussion: 324-5.
3. White RA, Miller DC, Criado FJ, Dake MD, Diethrich EB, Greenberg
RK, et al. Report on the results of thoracic endovascular aortic repair for
acute, complicated, type B aortic dissection at 30 days and 1 year from
a multidisciplinary subcommittee of the society for vascular surgery
Outcomes Committee. J Vasc Surg 2011;53:1082-90.
4. Thrumurthy SG, Karthikesalingam A, Patterson BO, Holt PJ,
Hinchliffe RJ, Loftus IM, et al. A systematic review of mid-term
outcomes of thoracic endovascular repair (TEVAR) of chronic type B
aortic dissection. Eur J Vasc Endovasc Surg 2011;42:632-47.
5. Nienaber CA, Rousseau H, Eggebrecht H, Kische S, Fattori R, Rehders
TC, et al. Randomized comparison of strategies for type B aortic
dissection: the INvestigation of STEnt Grafts in Aortic Dissection
(INSTEAD) trial. Circulation 2009;120:2519-28.
6. Nienaber CA. INSTEAD trial 5-year update. Presented at the American
Heart Association Meeting, Orlando, Florida; 2011.
7. Kang WC, Greenberg RK, Mastracci TM, Eagleton MJ, Hernandez
AV, Pujara AC, et al. Endovascular repair of complicated chronic distal
aortic dissections: intermediate outcomes and complications. J Thorac
Cardiovasc Surg 2011;142
s with preoperative evidence of infrarenal dissection vs
.atient8. Parsa CJ, Williams JB, Bhattacharya SD, Wolfe WG, Daneshmand MA,
McCann RL, et al. Midterm results with thoracic endovascular aortic
11
JOURNAL OF VASCULAR SURGERY
September 2012650 Andacheh et alrepair for chronic type B aortic dissection with associated aneurysm.
J Thorac Cardiovasc Surg 2011;141:322-7.
9. Resch TA, Delle M, Falkenberg M, Ivancev K, Konrad P, Larzon T, et al.
Remodeling of the thoracic aorta after stent grafting of type B dissection: a
Swedish multicenter study. J Cardiovasc Surg 2006;47:503-8.
10. Rodriguez JA, Olsen DM, Lucas L, Wheatley G, Ramaiah V, Diethrich
EB. Aortic remodeling after endografting of thoracoabdominal aortic
dissection. J Vasc Surg 2008;47:1188-94.
11. Karmonik C, Duran C, Diapn S, Anaya-Ayala JE, Davies MG, Lumsden
AB, et al. Quantification of changes in septal motion during follow-up
in aortic dissections. J Vasc Surg 2011;53:22S-3S. S
2008 to 2010. Of the 34 patients treated with Talent grafts, two
patients were complicated with a device-related retrograde dissec-
t
V
T
c
t
r
b
d
e
o
e
s
s
e
o
s
t
o
f
a
m
t2. Eggebrecht H, Nienaber CA, Neuhäuser M, Baumgart D, Kische S,
Schmermund A, et al. Endovascular stent-graft placement in aortic
dissection: a meta-analysis. Eur Heart J 2006;27:489-98.
3. Nienaber CA, Kische S, Zeller T, Rehders TC, Schneider H, Lorenzen
B, et al. Provisional extension to induce complete attachment after
Stent-graft placement in type B aortic dissection: the PETTICOAT
concept. J Endovasc Ther 2006;13:738-46.ubmitted Oct 31, 2011; accepted Feb 22, 2012.DISCUSSION
Dr Ben Starnes (Seattle, Wash). I have the following ques-
tions for the authors:
The goal of this therapy is to prevent death due to aneurysm
rupture and NOT to treat the underlying dissection. Did any
patient in this series continue to expand over the follow-up period,
and more importantly, did any patient go on to rupture and die?
Dr Iden David Andacheh. Given the fact that our study
population was part of an FDA-approved investigational device
exemption (IDE), patient mortality has been closely followed. As
previously mentioned, there were two cases of rupture within the
30-day postoperative period. Since the publication of these data,
we have had two patients who required debranching procedures as
a result infrarenal aortic expansion during long-term follow-up.
No patient has died due to rupture during long-term follow-up.
Dr Starnes. Described in this series are four cases of retro-
grade aortic dissection leading to death. The Medtronic Talent
device has an uncovered proximal stent to aid in fixation and
the company recently added a tip-capture mechanism (Valiant-
Captivia) to avoid a commonly observed deployment deficiency
described as “retroflexion” of this uncovered stent. Do the authors
believe that this device, with its uncovered proximal stent, is the
best device for managing dissections, and furthermore, have any
lethal retrograde dissections been observed since using the new
graft?
Dr Andacheh. Our institution used the Medtronic Talent
device from 2002 to 2007 and the Valiant-Captivia device fromion. By comparison, one out of the 39 patients treated with
aliant-Captivia grafts had a device-related retrograde dissection.
his may suggest a benefit to using the Valiant-Captivia device, but
learly, further analysis is needed.
Dr Starnes. As we all know, most type B dissections begin at
he left subclavian artery and thus an adequate proximal seal may
equire a debranching procedure such as a carotid-subclavian
ypass to achieve success. How often was a debranching procedure
one in this series? Along those lines, what was the rate of type I
ndoleak?
Dr Andacheh. A debranching procedure was required in four
ut of the 72 treated patients. Of the seven patients treated for
ndoleak, four were for a type I endoleak.
Dr Starnes. What was the role of neural protection in your
eries to prevent the dreaded complication of paraplegia? Was
pinal drainage used, and if so, what were the indications to do so?
Dr Andacheh. Spinal drain was not routinely used. Intraop-
rative maintenance of MAP pressures was used to reduce the risk
f paraplegia. Placement of a spinal drain was considered when
ubclavian artery coverage was required.
Dr Starnes. Finally, can the authors please expand on any
echniques or strategies for obliterating false lumen flow with coils
r glue or some sort of obliterative therapy to increase rates of
avorable aortic remodeling?
Dr Andacheh.We have not used coils, glue, or other obliter-
tive therapies. We rely on adequate proximal exclusion and re-
odeling of the aorta. We have only intervened by adding addi-
ional devices when the source of aortic expansion was identified.
